KIORA PHARMACEUTICALS, INC. Business Acquisition, Pro Forma Net Income (Loss)
KIORA PHARMACEUTICALS, INC. (KPRX) reported Business Acquisition, Pro Forma Net Income (Loss) of -$13.28 million for the 12-month period ending 2016-12-31, per its 10-K filed 2017-02-23.
Discontinued › Expense Statement › Operating Expenses
us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss · last filed 2017-02-23
- KIORA PHARMACEUTICALS, INC. business acquisition, pro forma net income (loss) for the quarter ending 2016-12-31 was -$3.70M.
- KIORA PHARMACEUTICALS, INC. business acquisition, pro forma net income (loss) for the quarter ending 2016-09-30 was -$3.47M.
- KIORA PHARMACEUTICALS, INC. business acquisition, pro forma net income (loss) for the quarter ending 2016-06-30 was -$3.73M, a 156.31% decline year-over-year.
- KIORA PHARMACEUTICALS, INC. business acquisition, pro forma net income (loss) for the quarter ending 2016-03-31 was -$2.38M.
- KIORA PHARMACEUTICALS, INC. business acquisition, pro forma net income (loss) for fiscal 2016 was -$13.28M.
- KIORA PHARMACEUTICALS, INC. business acquisition, pro forma net income (loss) for fiscal 2015 was -$17.30M.
| Period end | Business Acquisition, Pro Forma Net Income (Loss) 3 month | Business Acquisition, Pro Forma Net Income (Loss) 6 month | Business Acquisition, Pro Forma Net Income (Loss) 9 month | Business Acquisition, Pro Forma Net Income (Loss) 12 month |
|---|---|---|---|---|
| 2016-12-31 | -$3.70M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-23 | -$7.17M derived: sum of 2 quarters · filed 2017-02-23 | -$10.90M derived: sum of 3 quarters · filed 2017-02-23 | -$13.28M 10-K · filed 2017-02-23 |
| 2016-09-30 | -$3.47M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-01 | -$7.20M derived: sum of 2 quarters · filed 2016-11-01 | -$9.58M 10-Q · filed 2016-11-01 | -$21.19M derived: sum of 4 quarters · filed 2017-02-23 |
| 2016-06-30 | -$3.73M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-10 | -$6.11M 10-Q · filed 2016-08-10 | -$17.72M derived: sum of 3 quarters · filed 2017-02-23 | -$19.03M derived: sum of 4 quarters · filed 2017-02-23 |
| 2016-03-31 | -$2.38M 10-Q · filed 2016-05-13 | -$13.99M derived: sum of 2 quarters · filed 2017-02-23 | -$15.30M derived: sum of 3 quarters · filed 2017-02-23 | -$8.67M derived: sum of 4 quarters · filed 2017-02-23 |
| 2015-12-31 | -$11.61M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-23 | -$12.92M derived: sum of 2 quarters · filed 2017-02-23 | -$6.29M derived: sum of 3 quarters · filed 2017-02-23 | -$17.30M 10-K · filed 2017-02-23 |
| 2015-09-30 | -$1.31M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-01 | $5.32M derived: sum of 2 quarters · filed 2016-11-01 | -$5.69M 10-Q · filed 2016-11-01 | |
| 2015-06-30 | $6.63M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-10 | -$4.38M 10-Q · filed 2016-08-10 | ||
| 2015-03-31 | -$11.01M 10-Q · filed 2016-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |